Amneal Pharmaceuticals, Inc. Class A AMRX 深 沪
等待开盘 08-10 09:30:00 美东时间
18.14
+0.070
+0.39%
华盛通- 最 高19.15
- 今 开18.15
- 成交量 100.82万股
- 最 低 17.93
- 昨 收 18.07
- 总市值 273.91万
- 52周最高 19.26
- 市盈率 静 259.14
- 换手率 667.68%
- 52周最低 9.20
- 委 比 18.92%
- 总股本 0.00亿
- 历史最高 24.48
- 量 比 0.44
- 振 幅 6.75%
- 历史最低 1.21
- 每 手 1
- 风险率 2.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties
On July 6, 2026, Alkermes plc (the "Company") and Amneal Pharmaceuticals LLC ("Amneal") terminated the previously disclosed Authorized Generic Product Supply Agreement entered into on September 9, 2025
07-08 20:10
Amneal Pharmaceuticals Romidepsin Injection Solution Receives FDA Approval
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's romidepsin injection solution, 27.5 mg/5.5 mL, supplied
06-04 20:05
FDA Takes Step Forward on Testosterone Therapy for Men
https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men
04-16 23:37
Generic Drugs Focused Amneal Pharmaceuticals Revenue Crosses $800 Million
Amneal beats fourth-quarter earnings and revenue estimates, driven by CREXONT sales, and guides up to $1.03 in 2026 earnings.
02-27 22:17
Earnings Outlook For Amneal Pharmaceuticals
Amneal Pharmaceuticals (NASDAQ:AMRX) will release its quarterly earnings report...
02-26 22:01
Amneal Pharmaceuticals Gets FDA's Approval For Biologics Licensing Applications For Boncresa, Oziltus
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug
2025-12-23 05:02
Amneal Pharmaceuticals Announces FDA's Approval For Albuterol Sulfate Inhalation Aerosol
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's albuterol sulfate inhalation aerosol (90 mcg per
2025-12-02 21:09
Amneal Pharmaceuticals Announces U.S. FDA Approves Its Iohexol Injection
Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NASDAQ:AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic
2025-11-14 05:03
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
Amneal Pharmaceuticals获FDA批准其1%泼尼松龙乙酸酯眼用悬液，计划于2025年第三季度上市。该药物用于治疗 steroid-responsive ocular inflammation， IQVIA数据显示2025年销售额约为2.01亿美元。
2025-06-12 12:00
Amneal to Participate at Upcoming Investor Conferences in June
Amneal Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 5 and Goldman Sachs Global Healthcare Conference on June 10, with executives presenting and a live webcast available.
2025-05-29 20:05
